Sanofi Consumer Healthcare and China Resources Sanjiu Sign Strategic Cooperation Agreement at the 5th CIIE

Actively Foster Ecosystem Collaboration to Share Innovation and Development Opportunities

ShanghaiNovember 7, 2022PR Newswire -- Sanofi Consumer Healthcare signed a strategic cooperation agreement with CR SANJIU during the Fifth China International Import Expo (hereinafter referred to as "CIIE").This strategyThe collaboration highlights Sanofi Consumer Healthcare's emphasis on industry ecosystem partnerships, as well as its determination to continuously increase investment in the Chinese market. Additionally, Sanofi Consumer Healthcare also showcased at booth A3-02, hall 7.2 of the Medical Equipment and Health Products Exhibition Area during this CIIE.ExhibitedTen products, covering eight core categories including liver health, allergy relief, digestive health, vitamins and minerals, bone health, skin care, sleep aid, and pain relief, meet the daily health and wellness needs of Chinese consumers with a diversified product portfolio.

Group Photo at the Signing Ceremony of Sanofi and CR SANJIU

"We sincerely thank the CIIE for this excellent opportunity to promote win-win cooperation among multiple parties, bringing together resources from all over the world.First-class"Enterprises gather in Shanghai, helping us accelerate the 'speed' and explore new models of ecosystem cooperation," said Ms. Chen Xi, General Manager of Sanofi's Consumer Healthcare Business in China. "Sanofi Consumer Healthcare has always been committed to providing innovative self-care solutions for people, and the realization of this vision cannot be achieved without the full cooperation of all ecosystem partners. As more and more cooperative projects are implemented in the future, we look forward to bringing more and better daily healthcare products to Chinese consumers."

Ms. Chen Xi, General Manager of Sanofi Consumer Healthcare China, delivered a speech on site.

Continuing the Success Story, Embracing a Decade-Long Commitment: Collaboratively Building a Leading Brand in Liver Health

The collaboration between Sanofi Consumer Healthcare and CR SANJIU began in 2016. Their key cooperative product, "Essentiale," has gained significant industry recognition and holds a leading share in the oral liver health category. Currently, Essentiale is available in 11,000 hospitals and 130 fatty liver centers across China, helping approximately 4.2 million patients with fatty liver improve their liver health. To ensure convenient access to medication, Essentiale is stocked in 108,000 pharmacies and 5,800 "Perfect Pharmacies" nationwide. Additionally, to raise public awareness about liver health, as of September 2022, Sanofi Consumer Healthcare has provided free liver ultrasound screenings to 120,000 people in China and conducted patient education initiatives that have reached over 2 million people cumulatively.

Based on years of solid cooperation and trust, the two parties renewed a ten-year strategic cooperation agreement for the product "Essentiale". In the next decade, both sides will further deepen their cooperation, complement each other's advantages, and jointly focus on the liver health field.

Group Photo at the Signing Ceremony of Sanofi and CR SANJIU

At the same time, Sanofi has newly launched "Essentiale Light," the sister brand of Essentiale, further enhancing its liver care product line to meet the growing daily liver protection needs of Chinese consumers. Sanofi will continue to focus on the needs of Chinese patients and strive to provide higher quality liver care products for Chinese consumers.

In addition to the liver field, Sanofi's consumer health pharmaceuticals division's anti-allergy brand "Allegra" will also officially enter China's anti-allergy market. Allegra prioritizes the needs of Chinese patients, continuously deepening its expertise in the anti-allergy sector, and will safeguard a wide range of allergy sufferers in China with 25 years of industry experience.

In the future, Sanofi Consumer Healthcare will continue to leverage the channel and brand advantages of CR SANJIU to bring higher quality and diversified products to Chinese consumers, conveying Sanofi's corporate philosophy of "Chasing the Miracles of Life" and cutting-edge global scientific research achievements, jointly contributing to the vision of "Healthy China 2030".

Ms. Zhou Hui, Vice President of CR SANJIU, delivered a speech on site.

Locally Developed, Locally Expanded: Accelerating the Creation of a Bone Health Brand Better Suited for the Chinese Market

Since entering the Chinese consumer healthcare market, Sanofi Consumer Health has been committed to introducing and developing high-quality products that better suit Chinese consumers. Oscillex^®It is a professional bone health brand under Sanofi, originating from Australia, with over 98 years of dedication to the research, development, and production of bone and joint health products. It provides solutions for bone, joint, and muscle health applicable to every stage of life, tailored to different age groups.

Recently, OsteLin^®Signed a Strategic Cooperation Agreement with Huatai Dachang Pharmaceuticals. Both parties will fully leverage their respective resource advantages to empower China's Greater Health Market. Sanofi China's Innovation and R&D Team, based on research targeting Chinese consumers, will earnestly implement the brand philosophy of "In China, For China," achieving local R&D and local expansion to bring more and better bone health products to Chinese consumers.